|
| Overall
(n = 1342) | MPI risk group | P value |
Low risk
(n = 1153) | Moderate/severe risk (n = 189) |
|
| Sex (male), n (%) | 704 (52.5) | 638 (55.3) | 66 (34.9) | <0.0001 |
| Age (years), mean ± SD | 73.3 ± 5.5 | 72.9 ± 5.3 | 75.8 ± 6.1 | <0.0001 |
| Systolic blood pressure (mmHg), mean ± SD | 138.3 ± 16.9 | 138.3 ± 16.8 | 138.6 ± 18.1 | 0.8404 |
| Diastolic blood pressure (mmHg), mean ± SD | 77.7 ± 8.6 | 77.8 ± 8.5 | 77.4 ± 9.2 | 0.6096 |
| Heart rate, mean ± SD | 74.3 ± 8.6 | 74.3 ± 8.5 | 74.3 ± 8.9 | 0.9727 |
| Duration of diabetes (years), mean ± SD | 11.3 ± 8.2 | 11.1 ± 8.1 | 12.4 ± 8.9 | 0.0399 |
| Number of antidiabetic drugs, median | 2 (1, 2) | 1 (1, 2) | 2 (1, 2) | <0.0001 |
| Hypoglycemic events in the last 3 months, n (%) | 161 (12.0) | 122 (10.6) | 39 (20.6) | <0.0001 |
| Hospitalization for glycemic decompensation, n (%) | 30 (2.2) | 13 (1.1) | 17 (9.0) | <0.0001 |
| Gained weight, (%) | 256 (19.1) | 202 (17.5) | 54 (28.6) | 0.0003 |
| Diabetes complications, (%) | | | | |
| Coronary disease | 256 (20.0) | 194 (17.6) | 62 (34.6) | <0.0001 |
| Cerebrovascular disease | 148 (11.3) | 100 (8.9) | 48 (26.8) | <0.0001 |
| Peripheral arteriopathy | 268 (20.7) | 200 (17.9) | 68 (37.8) | <0.0001 |
| Nephropathy | 212 (16.2) | 159 (14.1) | 53 (29.3) | <0.0001 |
| Retinopathy | 241 (18.6) | 183 (16.3) | 58 (33.0) | <0.0001 |
| Neuropathy | 188 (15.0) | 138 (12.7) | 50 (30.3) | <0.0001 |
| Laboratory test | | | | |
| Glycaemia, (mg/dL) mean ± SD | 138.5 ± 35.4 | 138.7 ± 36.3 | 137.2 ± 29.9 | 0.5857 |
| Creatinine, (mg/dL) median | 0.90 (0.78, 1.10) | 0.90 (0.70, 1.10) | 0.98 (0.80, 1.30) | 0.0014 |
| HDL cholesterol, (mg/dL) mean ± SD | 49.9 ± 12.9 | 49.9 ± 13.0 | 49.7 ± 12.7 | 0.8005 |
| Triglycerides, (mg/dL) median | 117.0 (88.0, 158.0) | 115.0 (86.0, 154.0) | 132.0 (98.0, 177.0) | <0.0001 |
| HbA1c, (%) mean ± SD | 7.1 ± 1.0 | 7.1 ± 1.1 | 7.2 ± 1.0 | 0.4413 |
| BMI, (%) | | | | 0.0008 |
| Underweight (BMI < 18.5 kg/m2) | 3 (0.2) | 2 (0.2) | 1 (0.5) | |
| Normal weight (BMI 18.5–25 kg/m2) | 245 (18.3) | 210 (18.2) | 35 (18.5) | |
| Overweight (BMI 25–30 kg/m2) | 550 (41.0) | 495 (42.9) | 55 (29.1) | |
| Obese (BMI ≥ 30 kg/m2) | 544 (40.5) | 446 (38.7) | 98 (51.9) | |
| Antidiabetic therapies currently being taken, n (%) | | | | |
| Insulin (in combination with other drugs including sulfonylureas) | 62 (4.6) | 42 (3.6) | 20 (10.6) | <0.0001 |
| Insulin (in combination with other drugs excluding sulfonylureas) | 69 (5.1) | 54 (4.7) | 15 (7.9) | |
| Sulfonylureas (alone or in combination with other drugs excluding insulin) | 672 (50.1) | 570 (49.4) | 102 (54.0) | |
| Only biguanides | 399 (29.7) | 368 (31.9) | 31 (16.4) | |
| Only alpha-glucosidase inhibitors | 12 (0.9) | 9 (0.8) | 3 (1.6) | |
| Only thiazolidinediones | 12 (0.9) | 10 (0.9) | 2 (1.1) | |
| Biguanides and thiazolidinediones | 31 (2.3) | 27 (2.3) | 4 (2.1) | |
| Dpp-4 inhibitors (alone or in combination with other drugs) | 83 (6.2) | 71 (6.2) | 12 (6.4) | |
| Other associations | 2 (0.2) | 2 (0.2) | 0 (0.0) | |
|
